Nicola Specchio

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6281171/publications.pdf

Version: 2024-02-01

189 papers	8,036 citations	66250 44 h-index	78623 77 g-index
196 all docs	196 docs citations	196 times ranked	7079 citing authors

#	Article	IF	Citations
1	Fenfluramine significantly reduces dayâ€toâ€day seizure burden by increasing number of seizureâ€free days and time between seizures in patients with Dravet syndrome: A timeâ€toâ€event analysis. Epilepsia, 2022, 63, 130-138.	2.6	22
2	The epilepsyâ€“autism spectrum disorder phenotype in the era of molecular genetics and precision therapy. Epilepsia, 2022, 63, 6-21.	2.6	22
3	Vaccination and childhood epilepsies. European Journal of Paediatric Neurology, 2022, 36, 57-68.	0.7	3
4	Neurophysiological Findings in Neuronal Ceroid Lipofuscinoses. Frontiers in Neurology, 2022, 13, 845877.	1.1	7
5	Current role of surgery for tuberous sclerosis complexâ€associated epilepsy. Pediatric Investigation, 2022, 6, 16-22.	0.6	6
6	Modeling PCDH19-CE: From 2D Stem Cell Model to 3D Brain Organoids. International Journal of Molecular Sciences, 2022, 23, 3506.	1.8	1
7	International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions. Epilepsia, 2022, 63, 1398-1442.	2.6	263
8	Methodology for classification and definition of epilepsy syndromes with list of syndromes: Report of the ILAE Task Force on Nosology and Definitions. Epilepsia, 2022, 63, 1333-1348.	2.6	84
9	International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia, 2022, 63, 1443-1474.	2.6	81
10	ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia, 2022, 63, 1349-1397.	2.6	237
11	ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia, 2022, 63, 1475-1499.	2.6	148
12	The 50th anniversary of the Italian League Against Epilepsy (Lega Italiana Contro lâ€™Epilessia). Epilepsy and Behavior Reports, 2022, 19, 100553.	0.5	0
13	Epilepsy Course and Developmental Trajectories in STXBP1 -DEE. Neurology: Genetics, 2022, 8, .	0.9	24
14	An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a <scp>realâ€world</scp> practice setting: A report from the Fenfluramine European Early Access Program. Epilepsia Open, 2022, 7, 578-587.	1.3	15
15	Genetic causes of rare and common epilepsies: What should the epileptologist know?. European Journal of Medical Genetics, 2022, 65, 104570.	0.7	4
16	Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy. Drugs, 2021, 81, 101-123.	4.9	35
17	Developmental and epileptic encephalopathies: what we do and do not know. Brain, 2021, 144, 32-43.	3.7	81
18	Vagus nerve stimulation in patients with Lennoxâ€Gastaut syndrome: A metaâ€analysis. Acta Neurologica Scandinavica, 2021, 143, 497-508.	1.0	20

#	Article	IF	Citations
19	Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration. Clinical and Translational Science, 2021, 14, 635-644.	1.5	4
20	Impact of the COVIDâ€19 lockdown on patients and families with Dravet syndrome. Epilepsia Open, 2021, 6, 216-224.	1.3	15
21	A survey of the European Reference Network EpiCARE on clinical practice for selected rare epilepsies. Epilepsia Open, 2021, 6, 160-170.	1.3	3
22	Surgery for drugâ€resistant tuberous sclerosis complexâ€associated epilepsy: who, when, and what. Epileptic Disorders, 2021, 23, 53-73.	0.7	17
23	Developmental and epileptic encephalopathies: recognition and approaches to care. Epileptic Disorders, 2021, 23, 40-52.	0.7	48
24	Neuroimaging and genetic characteristics of malformation of cortical development due to mTOR pathway dysregulation: clues for the epileptogenic lesions and indications for epilepsy surgery. Expert Review of Neurotherapeutics, 2021, 21, 1-13.	1.4	2
25	Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients. Orphanet Journal of Rare Diseases, 2021, 16, 185.	1.2	17
26	Consensus statements on the information to deliver after a febrile seizure. European Journal of Pediatrics, 2021, 180, 2993-2999.	1.3	7
27	New paradigms for the treatment of pediatric monogenic epilepsies: Progressing toward precision medicine. Epilepsy and Behavior, 2021, , 107961.	0.9	4
28	Investigating health-related quality of life in rare diseases: a case study in utility value determination for patients with CLN2 disease (neuronal ceroid lipofuscinosis type 2). Orphanet Journal of Rare Diseases, 2021, 16, 217.	1.2	8
29	Infra-Occipital Supra-Tentorial Approach for Resection of Low-Grade Tumor of the Left Lingual Gyrus: 2-Dimensional Operative Video. Operative Neurosurgery, 2021, 21, E257-E258.	0.4	4
30	Juvenile myoclonic epilepsy: Long-term prognosis and risk factors. Brain and Development, 2021, 43, 688-697.	0.6	16
31	The Role of KRAS Mutations in Cortical Malformation and Epilepsy Surgery: A Novel Report of Nevus Sebaceous Syndrome and Review of the Literature. Brain Sciences, 2021, 11, 793.	1.1	14
32	Reply to Dravet, C. Different Outcomes of Acute Encephalopathy after Status Epilepticus in Patients with Dravet Syndrome. How to Avoid Them? Comment on â€œDe Liso et al. Fatal Status Epilepticus in Dravet Syndrome. Brain Sci. 2020, 10, 889â€. Brain Sciences, 2021, 11, 811.	1.1	0
33	Is Cenobamate the Breakthrough We Have Been Wishing for?. International Journal of Molecular Sciences, 2021, 22, 9339.	1.8	6
34	Imbalance of Systemic Redox Biomarkers in Children with Epilepsy: Role of Ferroptosis. Antioxidants, 2021, 10, 1267.	2.2	18
35	Epilepsy and BRAF Mutations: Phenotypes, Natural History and Genotype-Phenotype Correlations. Genes, 2021, 12, 1316.	1.0	13
36	Phenotypic overlap and genetic challenges in neurodevelopmental disorders. Developmental Medicine and Child Neurology, 2021, 63, 1368.	1.1	0

#	Article	IF	Citations
37	Cerliponase Alfa for the Treatment of Atypical Phenotypes of CLN2 Disease: A Retrospective Case Series. Journal of Child Neurology, 2021, 36, 468-474.	0.7	10
38	Identification of Geographic Sites Studying Photosensitivity. , 2021, , 323-335.		0
39	Red flags for neuronal ceroid lipofuscinosis type 2 disease. Developmental Medicine and Child Neurology, 2020, 62, 414-414.	1.1	3
40	A validation study of the clinical diagnosis of Dup15q syndrome: Which symptoms matter most?. Seizure: the Journal of the British Epilepsy Association, 2020, 74, 26-30.	0.9	3
41	Management of status epilepticus in adults. Position paper of the Italian League against Epilepsy. Epilepsy and Behavior, 2020, 102, 106675.	0.9	32
42	Trends in pediatric epilepsy surgery in Europe between 2008 and 2015: Countryâ€, centerâ€, and ageâ€specific variation. Epilepsia, 2020, 61, 216-227.	2.6	44
43	Early Onset Epilepsy Caused by Low-Grade Epilepsy-Associated Tumors and Focal Meningeal Involvement. Brain Sciences, 2020, 10, 752.	1.1	1
44	Wholeâ€exome and HLA sequencing in Febrile infectionâ€related epilepsy syndrome. Annals of Clinical and Translational Neurology, 2020, 7, 1429-1435.	1.7	15
45	Care Delivery for Children With Epilepsy During the COVID-19 Pandemic: An International Survey of Clinicians. Journal of Child Neurology, 2020, 35, 924-933.	0.7	48
46	Impact of COVID-19 pandemic on pediatric patients with epilepsy â€“ The caregiver perspective. Epilepsy and Behavior, 2020, 113, 107527.	0.9	21
47	POLG1-Related Epilepsy: Review of Diagnostic and Therapeutic Findings. Brain Sciences, 2020, 10, 768.	1.1	6
48	An accelerated shift in the use of remote systems in epilepsy due to the COVID-19 pandemic. Epilepsy and Behavior, 2020, 112, 107376.	0.9	29
49	GRIA3 missense mutation is cause of an x-linked developmental and epileptic encephalopathy. Seizure: the Journal of the British Epilepsy Association, 2020, 82, 1-6.	0.9	18
50	Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: A realâ€world study. Epilepsia, 2020, 61, 2405-2414.	2.6	37
51	Seizure outcome and use of antiepileptic drugs after epilepsy surgery according to histopathological diagnosis: a retrospective multicentre cohort study. Lancet Neurology, The, 2020, 19, 748-757.	4.9	177
52	Fatal Status Epilepticus in Dravet Syndrome. Brain Sciences, 2020, 10, 889.	1.1	11
53	Cannabidiol Treatment for Refractory Epilepsies in Pediatrics. Frontiers in Pharmacology, 2020, 11, 586110.	1.6	23
54	Newâ€onset refractory status epilepticus and febrile infectionâ€related epilepsy syndrome. Developmental Medicine and Child Neurology, 2020, 62, 897-905.	1.1	49

#	Article	IF	Citations
55	A standardized patient-centered characterization of the phenotypic spectrum of PCDH19 girls clustering epilepsy. Translational Psychiatry, 2020, 10, 127.	2.4	22
56	Autism and Epilepsy in Patients With Tuberous Sclerosis Complex. Frontiers in Neurology, 2020, 11, 639.	1.1	36
57	Developmental and epileptic encephalopathy due to SZT2 genomic variants: Emerging features of a syndromic condition. Epilepsy and Behavior, 2020, 108, 107097.	0.9	14
58	Refractory Status Epilepticus in Genetic Epilepsyâ€"Is Vagus Nerve Stimulation an Option?. Frontiers in Neurology, 2020, 11, 443.	1.1	8
59	Epileptogenic Network Formation. Neurosurgery Clinics of North America, 2020, 31, 335-344.	0.8	12
60	Improvement of quality of life in adolescents with epilepsy after an empowerment and sailing experience. Epilepsy and Behavior, 2020, 106, 106957.	0.9	3
61	Successful use of fenfluramine in nonconvulsive status epilepticus of Dravet syndrome. Epilepsia, 2020, 61, 831-833.	2.6	18
62	What are the epileptic encephalopathies?. Current Opinion in Neurology, 2020, 33, 179-184.	1.8	29
63	Quantitative MRI-Based Analysis Identifies Developmental Limbic Abnormalities in PCDH19 Encephalopathy. Cerebral Cortex, 2020, 30, 6039-6050.	1.6	12
64	Defining the phenotype of FHF1 developmental and epileptic encephalopathy. Epilepsia, 2020, 61, e71-e78.	2.6	11
65	Management of epileptic seizures in school-age children: Educational project dedicated to school staff. Epilepsy and Behavior, 2020, 105, 106951.	0.9	4
66	Reply to Dr. Capovilla on â€œReply to the article â€œManagement of status epilepticus in adults. Position paper of the Italian League Against Epilepsyâ€â€: Epilepsy and Behavior, 2020, 107, 107048.	0.9	0
67	Treatment of infantile spasms: why do we know so little?. Expert Review of Neurotherapeutics, 2020, 20, 551-566.	1.4	13
68	Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy . Therapeutics and Clinical Risk Management, 2020, Volume 16, 213-222.	0.9	34
69	Genotype-phenotype correlations in patients with de novo KCNQ2 pathogenic variants. Neurology: Genetics, 2020, 6, e528.	0.9	24
70	Source of cannabinoids: what is available, what is used, and where does it come from?. Epileptic Disorders, 2020, 22, 1-9.	0.7	6
71	Epilepsy and cannabidiol: a guide to treatment. , 2020, 22, 1-14.		46
72	The role of PCDH19 in refractory status epilepticus. Epilepsy and Behavior, 2019, 101, 106539.	0.9	8

#	Article	IF	Citations
73	De novo Absence Status Epilepticus in a pediatric cohort: Electroclinical pattern in a multicenter Italian patients cohort. Seizure: the Journal of the British Epilepsy Association, 2019, 73, 79-82.	0.9	6
74	Pediatric status epilepticus: Identification of prognostic factors using the new ILAE classification after 5 years of followâ€up. Epilepsia, 2019, 60, 2486-2498.	2.6	11
75	The Genetic Landscape of Epilepsy of Infancy with Migrating Focal Seizures. Annals of Neurology, 2019, 86, 821-831.	2.8	96
76	Expanding the clinical spectrum associated with PACS2 mutations. Clinical Genetics, 2019, 95, 525-531.	1.0	18
77	Paediatric Status Epilepticus. , 2019, , 503-515.		0
78	Generalized tonic seizures with autonomic signs are the hallmark of SCN8A developmental and epileptic encephalopathy. Epilepsy and Behavior, 2019, 96, 219-223.	0.9	25
79	Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients with Developmental and Epileptic Encephalopathy. Paediatric Drugs, 2019, 21, 283-290.	1.3	19
80	POGZâ€related epilepsy: Case report and review of the literature. American Journal of Medical Genetics, Part A, 2019, 179, 1631-1636.	0.7	19
81	Outcome after hemispherotomy in patients with intractable epilepsy: Comparison of techniques in the Italian experience. Epilepsy and Behavior, 2019, 93, 22-28.	0.9	30
82	Paediatric Status Epilepticus: identification of prognostic factors using the new ILAE classification. Epilepsy and Behavior, 2019, 101, 106745.	0.9	0
83	Berardinelliâ€Seip syndrome and progressive myoclonus epilepsy. Epileptic Disorders, 2019, 21, 117-121.	0.7	8
84	Persistent Treatment Effect of Cerliponase Alfa in Children with CLN2 Disease: A 3 Year Update from an Ongoing Multicenter Extension Study. , 2019, 50, .		0
85	Newâ€onset refractory status epilepticus (NORSE) and febrile infectionâ€"related epilepsy syndrome (FIRES): State of the art and perspectives. Epilepsia, 2018, 59, 745-752.	2.6	187
86	Study of Intraventricular Cerliponase Alfa for CLN2 Disease. New England Journal of Medicine, 2018, 378, 1898-1907.	13.9	348
87	Proposed consensus definitions for newâ€onset refractory status epilepticus (NORSE), febrile infectionâ€related epilepsy syndrome (FIRES), and related conditions. Epilepsia, 2018, 59, 739-744.	2.6	308
88	Defining the phenotypic spectrum of SLC6A1 mutations. Epilepsia, 2018, 59, 389-402.	2.6	99
89	Focal cortical dysplasia in genetic epilepsy: new insights from <scp>PCDH</scp>19â€related epilepsy. Developmental Medicine and Child Neurology, 2018, 60, 11-12.	1.1	6
90	Defining the electroclinical phenotype and outcome of PCDH19â€related epilepsy: A multicenter study. Epilepsia, 2018, 59, 2260-2271.	2.6	39

#	Article	IF	Citations
91	The phenotype of SCN8A developmental and epileptic encephalopathy. Neurology, 2018, 91, e1112-e1124.	1.5	114
92	Febrile Infectionâ€"Related Epilepsy Syndrome. , 2018, , 175-180.		1
93	EPINETLAB: A Software for Seizure-Onset Zone Identification From Intracranial EEG Signal in Epilepsy. Frontiers in Neuroinformatics, 2018, 12, 45.	1.3	13
94	FV 1183. Long-Term Safety and Efficacy of Intraventricular Enzyme Replacement Therapy in CLN2 Disease: 2-Year Results from an Ongoing Multicenter Extension Study. , 2018, 49, .		0
95	Clinical and genetic factors predicting Dravet syndrome in infants with SCN1A mutations. Neurology, 2017, 88, 1037-1044.	1.5	93
96	Reduced steroidogenesis in patients with <scp>PCDH</scp>19â€female limited epilepsy. Epilepsia, 2017, 58, e91-e95.	2.6	40
97	Management Strategies for CLN2 Disease. Pediatric Neurology, 2017, 69, 102-112.	1.0	80
98	Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. Brain, 2017, 140, 1316-1336.	3.7	426
99	Missense mutations of CACNA1A are a frequent cause of autosomal dominant nonprogressive congenital ataxia. European Journal of Paediatric Neurology, 2017, 21, 450-456.	0.7	37
100	Increasing volume and complexity of pediatric epilepsy surgery with stable seizure outcome between 2008 and 2014: A nationwide multicenter study. Epilepsy and Behavior, 2017, 75, 151-157.	0.9	27
101	Photosensitivity is an early marker of neuronal ceroid lipofuscinosis type 2 disease. Epilepsia, 2017, 58, 1380-1388.	2.6	50
102	Epilepsy surgery of â€œlow grade epilepsy associated neuroepithelial tumorsâ€• A retrospective nationwide Italian study. Epilepsia, 2017, 58, 1832-1841.	2.6	41
103	Rare GABRA3 variants are associated with epileptic seizures, encephalopathy and dysmorphic features. Brain, 2017, 140, 2879-2894.	3.7	33
104	<scp>PCDH</scp>19â€related epilepsy in two mosaic male patients. Epilepsia, 2016, 57, e51-5.	2.6	57
105	PCDH19-related epilepsy and Dravet Syndrome: Face-off between two early-onset epilepsies with fever sensitivity. Epilepsy Research, 2016, 125, 32-36.	0.8	28
106	Epilepsy in the setting of full trisomy 18: A multicenter study on 18 affected children with and without structural brain abnormalities. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2016, 172, 288-295.	0.7	24
107	Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis. Molecular Genetics and Metabolism, 2016, 119, 160-167.	0.5	70
108	Vigabatrin efficacy in <scp>GPR</scp>56â€associated polymicrogyria: The role of <scp>GABA_A</scp> receptor pathway. Epilepsia, 2016, 57, 1337-1338.	2.6	3

#	Article	IF	Citations
109	Benign myoclonus of early infancy. Journal of Pediatric Neurology, 2015, 08, 023-024.	0.0	2
110	Repetitive sleep starts. Journal of Pediatric Neurology, 2015, 08, 021-022.	0.0	0
111	Tonic reflex seizures of early infancy. Journal of Pediatric Neurology, 2015, 08, 033-034.	0.0	0
112	Mutation of <scp>CHRNA</scp>2 in a family with benign familial infantile seizures: Potential role of nicotinic acetylcholine receptor in various phenotypes of epilepsy. Epilepsia, 2015, 56, e53-7.	2.6	19
113	Seizing control of epileptic activity can improve outcome. Epilepsia, 2015, 56, 1482-1485.	2.6	28
114	Magnetic Resonance Fiber Tracking in a Neonate with Hemimegalencephaly. Journal of Neuroimaging, 2015, 25, 844-847.	1.0	10
115	Ictal vomiting as a sign of temporal lobe epilepsy confirmed by stereo-EEG and surgical outcome. Epilepsy and Behavior, 2015, 53, 112-116.	0.9	12
116	The phenotypic spectrum of SCN8A encephalopathy. Neurology, 2015, 84, 480-489.	1.5	246
117	Extending the use of stiripentol to other epileptic syndromes: A case of PCDH19-related epilepsy. European Journal of Paediatric Neurology, 2015, 19, 248-250.	0.7	14
118	Acute intralesional recording in hypothalamic hamartoma: description of 4 cases. Acta Neurologica Belgica, 2015, 115, 233-239.	0.5	6
119	Mutations of protocadherin 19 in female epilepsy (PCDH19-FE) lead to allopregnanolone deficiency. Human Molecular Genetics, 2015, 24, 5250-5259.	1.4	93
120	Mutations in the GABA Transporter SLC6A1 Cause Epilepsy with Myoclonic-Atonic Seizures. American Journal of Human Genetics, 2015, 96, 808-815.	2.6	173
121	CHD2 mutations are a rare cause of generalized epilepsy with myoclonicâ€“atonic seizures. Epilepsy and Behavior, 2015, 51, 53-56.	0.9	28
122	Claustrum damage and refractory status epilepticus following febrile illness. Neurology, 2015, 85, 1224-1232.	1.5	58
123	Cognitive development in females with PCDH19 gene-related epilepsy. Epilepsy and Behavior, 2015, 42, 36-40.	0.9	32
124	Characterizing PCDH19 in human induced pluripotent stem cells (iPSCs) and iPSC-derived developing neurons: emerging role of a protein involved in controlling polarity during neurogenesis. Oncotarget, 2015, 6, 26804-26813.	0.8	30
125	Occipital seizures induced by Intermittent Photic Stimulation in Dravet syndrome. Seizure: the Journal of the British Epilepsy Association, 2014, 23, 309-313.	0.9	10
126	Hemiconvulsionâ€“Hemiplegiaâ€“Epilepsy syndrome associated with inflammatory-degenerative hystopathological findings in child with congenital adrenal hyperplasia. European Journal of Paediatric Neurology, 2014, 18, 416-419.	0.7	2

#	Article	IF	Citations
127	Epilepsy in Menkes disease: An electroclinical long-term study of 28 patients. Epilepsy Research, 2014, 108, 1597-1603.	0.8	11
128	A novel mutation in the endosomal Na+/H+ exchanger NHE6 (SLC9A6) causes Christianson syndrome with electrical status epilepticus during slow-wave sleep (ESES). Epilepsy Research, 2014, 108, 811-815.	0.8	40
129	Hemispherotomy in Rasmussen encephalitis: Long-term outcome in an Italian series of 16 patients. Epilepsy Research, 2014, 108, 1106-1119.	0.8	41
130	Epilepsy in Patients With Duplications of Chromosome 14 Harboring FOXG1. Pediatric Neurology, 2014, 50, 530-535.	1.0	17
131	Video/EEG findings in a KCNQ2 epileptic encephalopathy: a case report and revision of literature data. Epileptic Disorders, 2013, 15, 158-165.	0.7	27
132	Vagus nerve stimulation in refractory epilepsy: New indications and outcome assessment. Epilepsy and Behavior, 2013, 28, 374-378.	0.9	31
133	Genetic testing in benign familial epilepsies of the first year of life: Clinical and diagnostic significance. Epilepsia, 2013, 54, 425-436.	2.6	110
134	PRRT2 is mutated in familial and non-familial benign infantile seizures. European Journal of Paediatric Neurology, 2013, 17, 77-81.	0.7	22
135	Vagus nerve stimulation for drug-resistant Epilepsia Partialis Continua: Report of four cases. Epilepsy Research, 2013, 107, 163-171.	0.8	20
136	Conventional magnetic resonance imaging and diffusion tensor imaging studies in children with novel GPR56 mutations: further delineation of a cobblestone-like phenotype. Neurogenetics, 2013, 14, 77-83.	0.7	23
137	Therapeutic approach to epileptic encephalopathies. Epilepsia, 2013, 54, 45-50.	2.6	74
138	Idiopathic focal epilepsies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 111, 591-604.	1.0	6
139	Electroencephalographic Features in Dravet Syndrome. Journal of Child Neurology, 2012, 27, 439-444.	0.7	34
140	Epilepsy in ring 14 chromosome syndrome. Epilepsy and Behavior, 2012, 25, 585-592.	0.9	17
141	Indicazioni e trattamento chirurgico della distonia dellâ€™etÃ pediatrica. Area Pediatrica, 2012, 13, 93-100.	0.0	0
142	Neonatal hemifacial spasm and fourth ventricle mass. Developmental Medicine and Child Neurology, 2012, 54, 697-703.	1.1	9
143	Focal seizures with affective symptoms are a major feature of PCDH19 geneâ€“related epilepsy. Epilepsia, 2012, 53, 2111-2119.	2.6	63
144	Rufinamide efficacy and safety as adjunctive treatment in children with focal drug resistant epilepsy: The first Italian prospective study. Epilepsy Research, 2012, 102, 94-99.	0.8	14

#	Article	IF	Citations
145	Somatic mosaicism of PCDH19 mutation in a family with low-penetrance EFMR. Neurogenetics, 2012, 13, 341-345.	0.7	27
146	PRRT2 Mutations are the major cause of benign familial infantile seizures. Human Mutation, 2012, 33, 1439-1443.	1.1	93
147	Prolonged episode of dystonia and dyskinesia resembling status epilepticus following acute intrathecal baclofen withdrawal. Epilepsy and Behavior, 2011, 21, 321-323.	0.9	15
148	Ictal yawning in a patient with drug-resistant focal epilepsy: Video/EEG documentation and review of literature reports. Epilepsy and Behavior, 2011, 22, 602-605.	0.9	3
149	Refractory focal epilepsy following acute encephalopathy with inflammation-mediated status epilepticus. Seizure: the Journal of the British Epilepsy Association, 2011, 20, 824-825.	0.9	4
150	Childhood refractory focal epilepsy following acute febrile encephalopathy. European Journal of Neurology, 2011, 18, 952-961.	1.7	19
151	Cognitive development in Dravet syndrome: A retrospective, multicenter study of 26 patients. Epilepsia, 2011, 52, 386-392.	2.6	99
152	Spectrum of phenotypes in female patients with epilepsy due to protocadherin 19 mutations. Epilepsia, 2011, 52, 1251-1257.	2.6	74
153	Acute-onset epilepsy triggered by fever mimicking FIRES (febrile infection-related epilepsy syndrome): The role of protocadherin 19 (PCDH19) gene mutation. Epilepsia, 2011, 52, e172-e175.	2.6	33
154	Febrile infectionâ€“related epilepsy syndrome (FIRES): Does duration of anesthesia affect outcome?. Epilepsia, 2011, 52, 28-30.	2.6	50
155	Febrile infection-related epilepsy syndrome (FIRES): Pathogenesis, treatment, and outcome. Epilepsia, 2011, 52, 1956-1965.	2.6	294
156	Parry-Romberg Syndrome and Rasmussen Encephalitis: Possible Association. Clinical and Neuroimaging Features. , 2011, 21, 188-193.		45
157	Myoclonic astatic epilepsy: An age-dependent epileptic syndrome with favorable seizure outcome but variable cognitive evolution. Epilepsy Research, 2011, 97, 133-141.	0.8	33
158	Diagnosing photosensitive epilepsy: Fancy new versus old fashioned techniques in patients with different epileptic syndromes. Brain and Development, 2011, 33, 294-300.	0.6	20
159	Migraine triggered by epileptic discharges in a Rasmussenâ€™s encephalitis patient after surgery. Brain and Development, 2011, 33, 597-600.	0.6	20
160	Ring 21 chromosome presenting with epilepsy and intellectual disability: Clinical report and review of the literature. , 2011, 155, 911-914.		13
161	Epileptic encephalopathy in children possibly related to immune-mediated pathogenesis. Brain and Development, 2010, 32, 51-56.	0.6	65
162	Efficacy of levetiracetam in the treatment of drug-resistant Rett syndrome. Epilepsy Research, 2010, 88, 112-117.	0.8	18

#	Article	IF	Citations
163	Panayiotopoulos syndrome: A clinical, EEG, and neuropsychological study of 93 consecutive patients. Epilepsia, 2010, 51, 2098-2107.	2.6	62
164	Rolandic epilepsy: An uncommon presentation with leg motor seizures. Epilepsia, 2010, 51, 2488-2491.	2.6	0
165	GPR56-related bilateral frontoparietal polymicrogyria: further evidence for an overlap with the cobblestone complex. Brain, 2010, 133, 3194-3209.	3.7	125
166	Idiopathic West Syndrome followed by childhood absence epilepsy. Seizure: the Journal of the British Epilepsy Association, 2010, 19, 597-601.	0.9	8
167	Documentation of autonomic seizures and autonomic status epilepticus with ictal EEG in Panayiotopoulos syndrome. Epilepsy and Behavior, 2010, 19, 383-393.	0.9	95
168	Benign Infantile Seizures or Watanabeâ€“Vigevano Syndrome. , 2010, , 865-870.		0
169	A novel de novo SCN1A missense mutation in Severe Myoclonic Epilepsy Borderland. Acta Neurologica Belgica, 2010, 110, 281-3.	0.5	0
170	The spectrum of benign myoclonus of early infancy: Clinical and neurophysiologic features in 102 patients. Epilepsia, 2009, 50, 1176-1183.	2.6	69
171	SCN1A duplications and deletions detected in Dravet syndrome: Implications for molecular diagnosis. Epilepsia, 2009, 50, 1670-1678.	2.6	152
172	Epileptic encephalopathies due to focal or unilateral brain lesion. Paediatrics and Child Health (United Kingdom), 2009, 19, S220-S225.	0.2	0
173	Effects of levetiracetam on EEG abnormalities in juvenile myoclonic epilepsy. Epilepsia, 2008, 49, 663-669.	2.6	54
174	Two Years' Follow-up of Rivastigmine Treatment in Huntington Disease. Clinical Neuropharmacology, 2007, 30, 43-46.	0.2	45
175	Clinical and electrophysiological features of epilepsy in Italian patients with CLN8 mutations. Epilepsy and Behavior, 2007, 10, 187-191.	0.9	26
176	Abnormalities of the contingent negative variation in Huntington's disease: Correlations with clinical features. Journal of the Neurological Sciences, 2007, 254, 84-89.	0.3	17
177	Brain MRI Findings in Severe Myoclonic Epilepsy in Infancy and Genotype?Phenotype Correlations. Epilepsia, 2007, 48, 1092-1096.	2.6	89
178	Autonomic Status Epilepticus in Panayiotopoulos Syndrome and Other Childhood and Adult Epilepsies: A Consensus View. Epilepsia, 2007, 48, 1165-1172.	2.6	102
179	Evidence for a rapid action of levetiracetam compared to topiramate in refractory partial epilepsy. Seizure: the Journal of the British Epilepsy Association, 2006, 15, 112-116.	0.9	8
180	A Novel SCN2A Mutation in Family with Benign Familial Infantile Seizures. Epilepsia, 2006, 47, 218-220.	2.6	74

#	Article	IF	Citations
181	Occurrence of a Prolonged Nonepileptic Motor Status after a Febrile Seizure. Epilepsia, 2006, 47, 1079-1081.	2.6	5
182	The spectrum of benign infantile seizures. Epilepsy Research, 2006, 70, 156-167.	0.8	55
183	Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy. Epilepsy Research, 2006, 71, 32-39.	0.8	72
184	Novel mutations in CLN8 in Italian variant late infantile neuronal ceroid lipofuscinosis: another genetic hit in the Mediterranean. Neurogenetics, 2006, 7, 111-117.	0.7	43
185	Efficacy of Levetiracetam in Huntington Disease. Clinical Neuropharmacology, 2005, 28, 280-284.	0.2	24
186	A Comparative Study of the Effect of Carbamazepine and Valproic Acid on the Pharmacokinetics and Metabolic Profile of Topiramate at Steady State in Patients with Epilepsy. Epilepsia, 2005, 46, 1046-1054.	2.6	26
187	Effects of rivastigmine on motor and cognitive impairment in Huntington's disease. Movement Disorders, 2004, 19, 1516-1518.	2.2	48
188	Citalopram as Treatment of Depression in Patients With Epilepsy. Clinical Neuropharmacology, 2004, 27, 133-136.	0.2	138
189	Features of the blink reflex in individuals at risk for Huntington's disease. Muscle and Nerve, 2001, 24, 1520-1525.	1.0	16